RMD Open

is an open access, peer-reviewed rheumatology journal from BMJ and EULAR, publishing original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 6.2
Citescore: 7.7
All metrics >>

Video Abstract

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

Conclusion: In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.

Find out more

EULAR Congress 2023

COVID-19 Content